{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:59Z","timestamp":1786649519938,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) presents a complex diagnostic challenge due to its heterogeneous nature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to examine the diagnostic utility of various hormones across different PCOS phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>This cross-sectional study was carried out in 187 newly diagnosed PCOS women (18\u201340 years) attending the outdoor clinics of the department of endocrinology and obstetrics and gynaecology of a tertiary care centre in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>One hundred and eighty-seven PCOS women based on revised Rotterdam 2003 criteria were recruited. Ninety-four age-matched healthy females were taken as controls. All PCOS women were categorised into four phenotypes (A, B, C and D) based on the National Institute of Health (2012) criteria. Detailed clinical examination and hormonal investigations including testosterone, androstenedione, dehydroepiandrosterone sulphate (DHEAS) and anti-M\u00fcllerian hormone (AMH) were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>The receiver operating characteristic curve (ROC) was generated to find the diagnostic utility of various hormones by using SPSS version 26.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The largest PCOS group was phenotype A (33.15%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 61) followed by phenotype B (28.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 52), phenotype D (23.9%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 44) and phenotype C (16.3%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 30). In ROC analysis, AMH and testosterone (except phenotype D) were good diagnostic parameters for PCOS. AMH cutoffs varied from 4.4 to 5.6 ng\/mL with sensitivities and specificities ranging from 86% to 97% and 85% to 100%, respectively, across all PCOS phenotypes. In the entire PCOS cohort, AMH at an optimal cutoff of 5.28 ng\/mL had sensitivity and specificity of 87% and 97%, respectively, for the diagnosis of PCOS. Optimal testosterone cutoffs were 29.3, 25.1 and 23.1 ng\/dL for phenotypes A, B and C, respectively, with reasonable sensitivities and specificities but not in phenotype D. Luteinising hormone (LH), follicle-stimulating hormone (FSH), LH\/FSH ratio, androstenedione and DHEAS had low-to-moderate sensitivity across all phenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>AMH is a useful hormonal diagnostic marker for PCOS across all phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jhrs.jhrs_152_24","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T05:01:29Z","timestamp":1735016489000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Utility of Various Hormones across Different Polycystic Ovary Syndrome Phenotypes: A Cross-sectional Study"],"prefix":"10.4103","volume":"17","author":[{"given":"Padala Ravi","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha Krishna","family":"Telagareddy","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, RK ENDOCARE, Rajahmundry, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Patro","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"R1-20241224","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod"},{"key":"R2-20241224","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"189","author":"Teede","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"R3-20241224","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R4-20241224","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1210\/jc.2003-030727","article-title":"Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome:Relationship to the ovarian follicle excess and to the follicular arrest","volume":"88","author":"Pigny","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20241224","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12905-022-01782-2","article-title":"Serum anti-m\u00fcllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age","volume":"22","author":"Butt","year":"2022","journal-title":"BMC Womens Health"},{"key":"R6-20241224","first-page":"157","article-title":"Cut-off levels of anti-mullerian hormone for the prediction of ovarian response, in vitro fertilization outcome and ovarian hyperstimulation syndrome","volume":"9","author":"Salmassi","year":"2015","journal-title":"Int J Fertil Steril"},{"key":"R7-20241224","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bpobgyn.2016.03.009","article-title":"Diagnostic criteria for PCOS:Is there a need for a rethink?","volume":"37","author":"Dewailly","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R8-20241224","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10815-013-0149-0","article-title":"Diagnosis of polycystic ovary syndrome:AMH in combination with clinical symptoms","volume":"31","author":"Sahmay","year":"2014","journal-title":"J Assist Reprod Genet"},{"key":"R9-20241224","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/andro.2021.0020","article-title":"Hyperandrogenism in women with polycystic ovarian syndrome: Pathophysiology and controversies","volume":"3","author":"Kanbour","year":"2022","journal-title":"Androgens Clin Res Ther"},{"key":"R10-20241224","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"R11-20241224","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/09513590.2017.1320377","article-title":"Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): An observational cross-sectional study","volume":"33","author":"Bhide","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"R12-20241224","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cca.2015.08.019","article-title":"Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome","volume":"450","author":"Bui","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R13-20241224","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/ijem.IJEM_646_17","article-title":"Study of visceral and subcutaneous abdominal fat thickness and its correlation with cardiometabolic risk factors and hormonal parameters in polycystic ovary syndrome","volume":"22","author":"Jena","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R14-20241224","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/ijem.IJEM_30_19","article-title":"Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene","volume":"23","author":"Sachdeva","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"R15-20241224","doi-asserted-by":"crossref","first-page":"569862","DOI":"10.5402\/2012\/569862","article-title":"Phenotype and metabolic disorders in polycystic ovary syndrome","volume":"2012","author":"G\u0142uszak","year":"2012","journal-title":"ISRN Endocrinol"},{"key":"R16-20241224","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/diagnostics12102313","article-title":"Comparing lean and obese PCOS in different PCOS phenotypes:Evidence that the body weight is more important than the rotterdam phenotype in Influencing the Metabolic Status","volume":"12","author":"Carmina","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R17-20241224","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41598-017-05717-y","article-title":"Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes","volume":"7","author":"Al-Jefout","year":"2017","journal-title":"Sci Rep"},{"key":"R18-20241224","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/jhrs.JHRS_149_18","article-title":"Establishing an anti-m\u00fcllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated anti-m\u00fcllerian hormone assay","volume":"12","author":"Mahajan","year":"2019","journal-title":"J Hum Reprod Sci"},{"key":"R19-20241224","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4103\/ijmr.IJMR_4608_20","article-title":"Serum anti-M\u00fcllerian hormone:A potential biomarker for polycystic ovary syndrome","volume":"158","author":"Halder","year":"2023","journal-title":"Indian J Med Res"},{"key":"R20-20241224","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13224-017-1066-4","article-title":"Role of AMH as diagnostic tool for polycystic ovarian syndrome","volume":"68","author":"Saxena","year":"2018","journal-title":"J Obstet Gynaecol India"},{"key":"R21-20241224","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1007\/s43032-023-01195-y","article-title":"Serum anti-mullerian hormone (AMH) levels among different PCOS phenotypes and its correlation with clinical, endocrine, and metabolic markers of PCOS","volume":"30","author":"Malhotra","year":"2023","journal-title":"Reprod Sci"},{"key":"R22-20241224","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.fertnstert.2015.12.023","article-title":"Comparative assessment of five serum antim\u00fcllerian hormone assays for the diagnosis of polycystic ovary syndrome","volume":"105","author":"Pigny","year":"2016","journal-title":"Fertil Steril"},{"key":"R23-20241224","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ajo.12366","article-title":"Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan","volume":"55","author":"Tremellen","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R24-20241224","doi-asserted-by":"crossref","first-page":"e0178120","DOI":"10.1371\/journal.pone.0178120","article-title":"Insulin resistance according to ?-cell function in women with polycystic ovary syndrome and normal glucose tolerance","volume":"12","author":"Song","year":"2017","journal-title":"PLoS One"},{"key":"R25-20241224","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00508-010-1426-x","article-title":"Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome","volume":"122","author":"Li","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"R26-20241224","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.gocm.2022.10.002","article-title":"Comparison of body mass index, anti-mullerian hormone and insulin resistance parameters among different phenotypes of polycystic ovary syndrome","volume":"2","author":"Gursu","year":"2022","journal-title":"Gynecol Obstet Clin Med"},{"key":"R27-20241224","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.fertnstert.2013.12.056","article-title":"Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National institutes of health 1990 criteria","volume":"101","author":"Salameh","year":"2014","journal-title":"Fertil Steril"},{"key":"R28-20241224","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/2230-8210.107858","article-title":"Clinical characteristics of polycystic ovary syndrome in Indian women","volume":"17","author":"Ramanand","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"R29-20241224","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/jcmm.16205","article-title":"The role of androgen and its related signals in PCOS","volume":"25","author":"Ye","year":"2021","journal-title":"J Cell Mol Med"},{"key":"R30-20241224","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jc.2013-3399","article-title":"Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: The utility of serum androstenedione","volume":"99","author":"O'Reilly","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20241224","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/jcm10010119","article-title":"Hyperandrogenism by liquid chromatography tandem mass spectrometry in PCOS:Focus on testosterone and androstenedione","volume":"10","author":"Grassi","year":"2020","journal-title":"J Clin Med"},{"key":"R32-20241224","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ando.2024.01.011","article-title":"Is it useful to measure DHEAS levels in PCOS?","volume":"85","author":"Boucher","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"key":"R33-20241224","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1210\/jc.2014-2569","article-title":"Adrenal androgen excess and body mass index in polycystic ovary syndrome","volume":"100","author":"Moran","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Human Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_152_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:59Z","timestamp":1786647299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_152_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jhrs.jhrs_152_24","relation":{},"ISSN":["0974-1208","1998-4766"],"issn-type":[{"value":"0974-1208","type":"print"},{"value":"1998-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-09-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}